Does the reason you own GE HealthCare Technologies Inc. Common Stock still hold?
Review the position using today's evidence. Identify what still supports it, what has changed, and what deserves another decision.
Price as of Nov 19, 2026, 9:15 AM UTC (polygon last daily bar) · Evidence through Nov 12, 2026
The current case for continuing to hold
The stored model values GE HealthCare Technologies Inc. Common Stock at $58.92 per share against $83.66, versus $41.64 at the previous review on Nov 12, 2026. The case rests on the conditions below.
| Reason to hold | Supporting evidence | Contrary evidence | Condition to review |
|---|---|---|---|
| Revenue growth (yr 1): 3.99%Supported by the reviewed evidence | Trailing 4-year revenue CAGR of 4.0%, faded toward terminal growth over 5 years. | None in the last 45 days | Re-underwrite if revenue growth, margins, or the cost of capital diverge materially from the stored assumptions. |
| Operating margin (steady-state): 13.24%Supported by the reviewed evidence | Anchored to mean operating margin of 13.2% across the last 4 reported periods. | None in the last 45 days | Re-underwrite if revenue growth, margins, or the cost of capital diverge materially from the stored assumptions. |
| Discount rate (WACC): 8.53%Changed since the previous review | CAPM baseline: 5.10% risk-free + β0.62 × 5.5% ERP = 8.53%. | None in the last 45 days | Re-underwrite if revenue growth, margins, or the cost of capital diverge materially from the stored assumptions. |
What changed since the previous review?
- Nov 19, 2026 · model $58.92 vs price $83.66 · discount rate 8.53% · Overvalued
- Nov 12, 2026 · model $41.64 vs price $84.03 · discount rate 10.38% · Overvalued
- Sep 21, 2026 · model $37.09 vs price $64.13 · discount rate 9.21% · Overvalued
- Nov 12, 2026 · GE HealthCare lifts 2026 organic revenue guidance to 4% on $23.7B backlog
- Nov 12, 2026 · GE HealthCare lifts 2026 organic revenue guidance to 4% with $23.7B equipment backlog
Review your holding.
The observation that deserves your attention
Discount rate (WACC): changed since the previous review.
Evidence to inspect: 10-yr UST (risk-free) (FRED DGS10); Equity beta (vs SPY, 1y) (Polygon daily bars, 252 date-matched days); Equity risk premium (Damodaran (institutional consensus)).
Make your next review start with what changed.
Save your reasons for holding, the assumptions they depend on, and the conditions you want monitored. When relevant evidence changes, reopen the position with the previous and revised cases side by side.
Should I buy?Should I sell?Should I hedge?How to hedgeImpact ledger